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ABSTRACT A screening of more than 1,500 drug-resistant strains of Mycobacterium
tuberculosis revealed evolutionary patterns characteristic of positive selection for
three alanine racemase (Alr) mutations. We investigated these mutations using mo-
lecular modeling, in vitro MIC testing, as well as direct measurements of enzymatic
activity, which demonstrated that these mutations likely confer resistance to
D-cycloserine.
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In 2015, the Global Drug Facility declared that the cost of D-cycloserine (DCS), a groupC drug to treat tuberculosis (TB), would be cut by more than half to as little as $0.19
per capsule to support the treatment of multidrug-resistant (MDR) and extensively
drug-resistant (XDR) TB, which represent a major threat to public health (1). In light of
this announcement, a better understanding of the resistance mechanisms to this drug
is required to facilitate phenotypic as well as genotypic drug susceptibility testing
(DST), both in the context of surveillance and individual patient treatment, to avoid the
severe side effects of this drug (2, 3).
Studies of the mode of action of DCS in mycobacteria have produced contradictory
results, with some studies pointing to alanine racemase (Alr) as the primary target and
others supporting D-alanine–D-alanine ligase (DdlA) (4–9). However, molecular data
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from Mycobacterium tuberculosis complex (MTBC) have implicated only alr in DCS
resistance, which can also be conferred by mutations in alanine dehydrogenase (ald) or
a permease (cycA) gene (10, 11). Using molecular modeling, we had predicted that the
alr M319T mutation observed in an XDR strain would likely confer resistance to DCS,
which was subsequently conﬁrmed by Desjardins et al. using the unrelated strain
TKK_04_0105 (see Table S1 in the supplemental material) (2, 11). Desjardins et al.
described a number of additional alr mutations in strains with elevated DCS MICs,
including a C-to-T nucleotide change 8 bp upstream of the experimentally conﬁrmed
start codon of alr (strain TKK_02_0050 in Table S1) (11, 12). This was notable, as Merker
et al. had previously reported that, compared with the susceptible parental alr wild-
type strain, the acquisition of this mutation during treatment with DCS correlated with
DCS resistance, which suggested that alr mutations might be both necessary and
sufﬁcient to confer DCS resistance (13).
To gain further insights into the impact of alr mutations, we ﬁrst conﬁrmed that the
aforementioned alr C-8T promoter mutant that evolved during treatment correlated in
MICs above the current World Health Organization (WHO)-endorsed critical concentra-
tion (CC) of 30 g/ml using the 1% proportion method on Löwenstein-Jensen (LJ)
(strains PBm0 and PBm14 in Table S1; Desjardins et al. and Merker et al. had used 10%
as the critical proportion and therefore had not adhered to the current WHO recom-
mendations [11, 13, 14]). Using the same method, we also showed that two strains with
alr M319T or Y364D mutations from XDR TB patients with a treatment history with DCS
had MICs above the CC (Table S1). Moreover, we observed the M319T mutation in three
XDR strains (PT1, PT2, and PT5) from Lisbon, Portugal (15). Although no CC exists for
MGIT 960, this mutation correlated in an MIC increase from 16 to 64 g/ml compared
with three closely related wild-type control strains (PT3, PT6, and PT7) and one more
distantly related control strain (PT4), which supported the role of this mutation in DCS
resistance (Fig. 1A; Table S1). In contrast, no or minimal MIC increases were recorded
when testing these Portuguese strains using Sensititre MycoTB plates (Table S1) (16).
Finally, a pre-XDR alr R373L mutant from a patient with DCS exposure, which also
harbored a deletion in ald, tested resistant on LJ using the 1% proportion method
(Tables S1 and S2).
To study the importance of the C-8T, M319T, Y364D, and R373L mutations from an
evolutionary perspective, we screened previously published and unpublished genomes
of more than 1,500 MDR strains (mostly from Germany, eastern Europe, and Swaziland),
which identiﬁed eight additional strains with mutations at these alr positions or codons
(Table S1). Interrogating the genomes of these 17 strains in the context of a phyloge-
netically diverse reference collection that included all major MTBC lineages and species
showed that the mutations had either been acquired multiple times independently
and/or that different amino acid changes were present at the same codons (Fig. 1B).
These mutation patterns are typically a signal of positive selection, which could have
occurred in response to DCS exposure.
Molecular modeling of these coding mutations supported this hypothesis. Alr
functions as a homodimer, aided by the cofactor pyridoxal 5=-phosphate (PLP) to which
it is covalently bound. DCS inhibits Alr irreversibly by covalently bonding to PLP (4). We
generated and analyzed a model of the complex between the M. tuberculosis Alr and
DCS (AlrMtb-DCS) (Fig. S1) (4, 17). Amino acid residues 319 and 364 were located directly
in the active site (Fig. S1B). M319T was positioned close enough to allow interaction
with the DCS moiety, which, given the large change of the character of the side chain,
could strongly affect DCS reactivity (Fig. S1C). Y364 is involved in the positioning of the
phosphate moiety of PLP and thus represents a prominent active site residue in the
conserved inner layer of the substrate entrance corridor of Alr (Fig. S1B) (17). A
mutation to aspartic acid introduced a shorter and negatively charged side chain, which
could potentially affect PLP orientation in the active site (Fig. S1C). Moreover, it could
inﬂuence DCS uptake through alteration of the entrance corridor. Interestingly, M319 is
located near Y364 and, as a result, it is possible that the M319T mutation could alter the
interaction with Y364, thereby affecting DCS inhibition. In contrast, the R373L mutation
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was not directly located within the active site but near the dimer interface and close to
residues M319 and D320, which play an important role in the makeup of the active site
(Fig. S1B). Consequently, the replacement of arginine with the short and hydrophobic
side chain of leucine might disrupt molecular interactions at the dimer interface as well
as destabilize the DCS binding site (Fig. S1C).
FIG 1 Maximum likelihood tree based on a concatenated sequence alignment of 45,740 variable sites (1,000
resamplings, general time-reversible [GTR] nucleotide substitution model) showing the alr mutants from Table S1
in the context of a globally representative reference collection of 287 MTBC strains. (A) Zoomed-in part of the
overall tree (B), showing the phylogenetic relationship between the three Portuguese M319T mutants (PT1, PT5,
and PT2) and the control strains (PT7, PT3, PT6, and PT4) tested in MGIT and Sensititre. The three Indian M319T,
R364D, and R373G mutants that were tested with the 1% proportion LJ method in this study are underlined. The
C-8T, M319T, and R364D mutations were homoplastic (i.e., they were acquired multiple times independently) and
two different amino acid changes were observed at codon 373 (i.e., R373L and R373G). Thus, all mutations show
evolutionary patterns of positive selection. SNPs, single-nucleotide polymorphisms; CAS, central Asian strain.
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To test these predictions experimentally, we expressed and puriﬁed the aforemen-
tioned AlrMtb-coding mutants, along with wild-type AlrMtb, and determined their half-
maximal inhibitory concentration (IC50) to measure the effectiveness of inhibition by
DCS (Fig. 2). The IC50 for wild-type AlrMtb was 26.4  1.7 M, which was in the range
previously reported for this compound (18, 19). From our structure-based analysis, we
expected the two mutations located in the active site to show the greatest effect on
DCS inhibition. Indeed, the M319T mutant enzyme showed minimal inhibition by DCS,
even at 1,000 M (Fig. 2). Thus, the IC50 of this mutant could not be determined. The
IC50 of the Y364D mutant showed a 50-fold increase to 1,328.0  340.0 M. The R373L
mutation, which was not located directly within the active site, also showed a signiﬁ-
cant increase in resistance to DCS, with an IC50 of 712.0  138.5 M (27-fold increase).
Taken together, these data suggested that alr mutations likely confer DCS resis-
tance, although allelic exchange experiments are required to formally prove this
(particularly for R373L, which coincided with a deletion in ald and, consequently, may
not be sufﬁcient to confer resistance on its own). Although the relationship between
MICs and IC50s can be complex, the observation that MICs increased by only 4- to
16-fold versus at least 25-fold increases for IC50s supports the notion that DCS inhibits
multiple targets, as noted earlier. This study should be complemented with extensive
MIC testing of phylogenetically diverse pansusceptible MTBC strains to deﬁne the
epidemiological cutoff value, given that it is unclear based on which evidence the
current WHO CC on LJ has been set (3, 14, 20, 21). Moreover, further MIC testing of likely
DCS-resistant strains is needed to investigate whether the Sensititre system is less
reliable at detecting DCS resistance than are LJ and MGIT. Finally, the impact of alr
mutations on resistance on terizidone remains to be investigated.
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